Parnassus Investments, an investment management firm, released its “Parnassus Value Equity Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.

In Reply We read the letters with great interest commenting on our recent article. We agree that surveillance bias is a concern in observational studies

To the Editor A recent article by Shor et al reported a doubling (adjusted hazard ratio, 2.21; 95% CI, 1.65-2.96) in the risk of neovascular

To the Editor We read with interest the cohort study by Shor et al evaluating glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and incident neovascular age-related

To the Editor We read the recent report on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and incident neovascular age-related macular degeneration (nAMD) with interest. Given

To the Editor We read with interest the study by Shor et al showing a 2-fold relative risk of newly diagnosed neovascular age-related macular degeneration

NEW YORK–(BUSINESS WIRE)–The 43rd Barometer from Sermo, a fast, frictionless HCP social engagement platform and leader in healthcare insights, shows that pharma-led direct-to-patient (DTP) GLP-1

Key Points Eli Lilly has been a dominant force in the GLP-1 market, and that looks set to continue. Pfizer’s acquisitions haven’t paid off yet

Novo Nordisk is seeking FDA approval for an experimental obesity shot, CagriSema (cagrilintide and semaglutide), according to a Dec. 18 news release from the Denmark-based

Novo Nordisk NVO is a leading player in the obesity market, driven by its blockbuster GLP-1 therapy Wegovy (semaglutide). However, despite being a core growth driver,

Top of the morning to you, and a fine one it is. Clear blue skies and pleasant breezes are enveloping the Pharmalot campus, where the

Mazdutide versus placebo in Chinese adults with type 2 diabetes  Nature Nature | Two Phase 3 Clinical Results of Mazdutide (GLP-1/GCG Dual Receptor Agonist) in Chinese

Babybel, the “small, ready-to-eat industrial cheese wrapped in its signature red wax”, is an unexpected beneficiary of anti-obesity drugs, said Le Monde. Its French-owned producer

Biomedicines, Vol. 13, Pages 3117: Multimodal Prehabilitation for Hernia Repair: Linking Metabolic Modulation and Mechanical Methods Biomedicines doi: 10.3390/biomedicines13123117 Authors: Dan Nicolae Paduraru Alexandru Cosmin

Lilly’s orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial  Eli Lilly Eli Lilly says

Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly  CNBC Novo Nordisk files for FDA approval of CagriSema, the first

Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound  CNBC Lilly’s orforglipron helped people maintain weight loss after switching from

In 2025, the wellness industry faced contradictions as consumers claimed healthy lifestyles but their use of gut-disrupting drugs told a different story. Despite this, there

Key Points Novo Nordisk’s new indications for semaglutide and its attractive pipeline could allow it to bounce back. Intuitive Surgical should remain the leader in

Can anyone stop Eli Lilly (NYSE: LLY)? The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many

CagriSema 2.4 mg/2.4 mg is an investigational fixed-dose injectable medicine that combines the novel amylin analogue, cagrilintide, with semaglutide to target complementary obesity-related pathways1,2 In

The move signals that we’re about to see a lot more GLP-1-centric menus. Chipotle is officially in its Ozempic era. 

Popular new anti-obesity medications can help people lose 10% to 20% of their body weight, yet a new study indicates that about 40% of those

Eli Lilly’s experimental obesity pill allowed patients who had lost weight on injected GLP-1-based drugs to keep most of the weight off for another year,

In ATTAIN-MAINTAIN, orforglipron achieved the primary and all key secondary endpoints for weight maintenance vs. placebo at 52 weeks following weight loss on Wegovy or

Metabolic adaptation to environmental changes, such as fasting and cold exposure, involves a dynamic shift in fuel utilization from glucose to fatty acid oxidation, a

Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for obesity.

Eli Lilly’s investigational obesity pill largely helped patients maintain their weight loss after they switched from the potent injectable treatments Wegovy and Zepbound, the company

Key Points These two healthcare stocks are top names to invest in, but they haven’t both been doing well of late. Eli Lilly has generated

When HCA Healthcare, one of the largest hospital systems in the U.S., recently told employees it would stop covering blockbuster obesity drugs Zepbound and Wegovy

A growing body of evidence suggests GLP-1 receptor agonists may improve survival as well as reduce chemotherapy-related toxicities in women with breast cancer. Medscape Medical

IJMS, Vol. 26, Pages 12163: GLP-1 Signalling as a Therapeutic Avenue in Parkinson’s Disease: A Comprehensive Review International Journal of Molecular Sciences doi: 10.3390/ijms262412163 Authors:

submitted by /u/Accurate_Cry_8937 [link] [comments]

SAN FRANCISCO and SUZHOU, China, Dec. 17, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes

(MedPage Today) — The dual GIP/GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound) was just as cardioprotective as the GLP-1 drug dulaglutide (Trulicity) in patients with type

What You Should Know:  – Weight Watchers has unveiled a massive platform overhaul integrating GLP-1 prescription management with a redesigned app featuring an AI body

Anna Sinaiko. Stephanie Mitchell/Harvard Staff Photographer Health Is cost curbing use of weight loss drugs? 40 percent of GLP-1 prescriptions go unfilled, study finds Alvin

Post Content

WEDNESDAY, Dec. 17, 2025 — Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) may protect against vertebral fractures in people with diabetes, according to a research

Vivian Ho and Salpy Kanimian in The Conversation: Some of the premium increases can be attributed to an increase in hospital outpatient visits and coverage of GLP-1 drugs.